FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938369099> ?p ?o ?g. }

• W2938369099 endingPage "759" @default.
• W2938369099 startingPage "753" @default.
• W2938369099 abstract "A recent increase in sterile intraocular inflammation after aflibercept (EYLEA; Regeneron Pharmaceuticals, Inc, Tarrytown, NY) injection was reported to the American Society of Retina Specialists' Research and Safety in Therapeutics Committee. This study describes their clinical characteristics and outcomes.Case series.Sixty-eight eyes of 66 patients (97% reported from May 2017 through February 2018).Exclusion criteria were intravitreal antibiotic injection and follow-up of less than 7 days. Diagnosis was at each physician's discretion.Presenting signs and symptoms, injection characteristics, management details, and visual outcomes.Mean time to presentation was 2.6 days (median, 2.0 days; range, 0-15 days). Symptoms included blurry vision (93%), floaters (60%), pain (44%), severe pain (6%), and photophobia (19%). Mean visual acuities before and after injection were 20/50 and 20/178, respectively. All patients showed intraocular inflammation: 24% with only vitritis, 16% with only anterior chamber reaction, and 60% with both. Less common findings included keratic precipitates (22%), corneal edema (13%), conjunctival injection (10%), chemosis (4%), hypopyon (4%), and fibrin (3%). Two patients were affected bilaterally. Treatment included topical steroids (93%), with 1% supplemented by oral steroids. Inflammation resolved in 79% at study completion (mean, 34 days; range, 7-105 days; 51% resolved by 1 month). This group's mean final visual acuity (VA) was 20/55, and 15% lost 2 lines or more. This vision loss was associated with shorter time to presentation (P < 0.0001), magnitude of decrease in presenting VA (P = 0.0004), presence of fibrin (P = 0.02), and trended toward receiving only observation (P = 0.10). There were no other presenting factors that significantly affected visual outcome. In patients with unresolved inflammation at the final visit, mean follow-up was 29 days, and mean final VA was 20/118. Overall, 26 aflibercept lots were involved.This is the largest study of aflibercept-related sterile intraocular inflammation, and is the only large report to exclude eyes injected with intraocular antibiotics. Most patients presented early with decreased VA and intraocular inflammation, but without injection, hypopyon, fibrin, or severe pain. Final VA remained decreased in a significant minority of patients." @default.
• W2938369099 created "2019-04-25" @default.
• W2938369099 creator A5000385343 @default.
• W2938369099 creator A5001994846 @default.
• W2938369099 creator A5011557910 @default.
• W2938369099 creator A5021512482 @default.
• W2938369099 creator A5033501830 @default.
• W2938369099 creator A5059308255 @default.
• W2938369099 creator A5065988752 @default.
• W2938369099 creator A5084423332 @default.
• W2938369099 creator A5091416305 @default.
• W2938369099 date "2019-09-01" @default.
• W2938369099 modified "2023-10-01" @default.
• W2938369099 title "Aflibercept-Related Sterile Intraocular Inflammation Outcomes" @default.
• W2938369099 cites W1455556003 @default.
• W2938369099 cites W1989312280 @default.
• W2938369099 cites W2004237626 @default.
• W2938369099 cites W2008309504 @default.
• W2938369099 cites W2015390714 @default.
• W2938369099 cites W2031531075 @default.
• W2938369099 cites W2036940508 @default.
• W2938369099 cites W2052892208 @default.
• W2938369099 cites W2083842106 @default.
• W2938369099 cites W2102012604 @default.
• W2938369099 cites W2104106986 @default.
• W2938369099 cites W2108364254 @default.
• W2938369099 cites W2117879837 @default.
• W2938369099 cites W2129525239 @default.
• W2938369099 cites W2130626478 @default.
• W2938369099 cites W2132366323 @default.
• W2938369099 cites W2286056081 @default.
• W2938369099 cites W2314092373 @default.
• W2938369099 cites W2316338492 @default.
• W2938369099 cites W2329117104 @default.
• W2938369099 cites W2331904769 @default.
• W2938369099 cites W2522843224 @default.
• W2938369099 cites W2743639829 @default.
• W2938369099 cites W4253875289 @default.
• W2938369099 doi "https://doi.org/10.1016/j.oret.2019.04.006" @default.
• W2938369099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31153850" @default.
• W2938369099 hasPublicationYear "2019" @default.
• W2938369099 type Work @default.
• W2938369099 sameAs 2938369099 @default.
• W2938369099 citedByCount "40" @default.
• W2938369099 countsByYear W29383690992019 @default.
• W2938369099 countsByYear W29383690992020 @default.
• W2938369099 countsByYear W29383690992021 @default.
• W2938369099 countsByYear W29383690992022 @default.
• W2938369099 countsByYear W29383690992023 @default.
• W2938369099 crossrefType "journal-article" @default.
• W2938369099 hasAuthorship W2938369099A5000385343 @default.
• W2938369099 hasAuthorship W2938369099A5001994846 @default.
• W2938369099 hasAuthorship W2938369099A5011557910 @default.
• W2938369099 hasAuthorship W2938369099A5021512482 @default.
• W2938369099 hasAuthorship W2938369099A5033501830 @default.
• W2938369099 hasAuthorship W2938369099A5059308255 @default.
• W2938369099 hasAuthorship W2938369099A5065988752 @default.
• W2938369099 hasAuthorship W2938369099A5084423332 @default.
• W2938369099 hasAuthorship W2938369099A5091416305 @default.
• W2938369099 hasConcept C118487528 @default.
• W2938369099 hasConcept C141071460 @default.
• W2938369099 hasConcept C2776694085 @default.
• W2938369099 hasConcept C2777802072 @default.
• W2938369099 hasConcept C2778257484 @default.
• W2938369099 hasConcept C2778749236 @default.
• W2938369099 hasConcept C2779714575 @default.
• W2938369099 hasConcept C2780347916 @default.
• W2938369099 hasConcept C2780590625 @default.
• W2938369099 hasConcept C2781403741 @default.
• W2938369099 hasConcept C71924100 @default.
• W2938369099 hasConceptScore W2938369099C118487528 @default.
• W2938369099 hasConceptScore W2938369099C141071460 @default.
• W2938369099 hasConceptScore W2938369099C2776694085 @default.
• W2938369099 hasConceptScore W2938369099C2777802072 @default.
• W2938369099 hasConceptScore W2938369099C2778257484 @default.
• W2938369099 hasConceptScore W2938369099C2778749236 @default.
• W2938369099 hasConceptScore W2938369099C2779714575 @default.
• W2938369099 hasConceptScore W2938369099C2780347916 @default.
• W2938369099 hasConceptScore W2938369099C2780590625 @default.
• W2938369099 hasConceptScore W2938369099C2781403741 @default.
• W2938369099 hasConceptScore W2938369099C71924100 @default.
• W2938369099 hasFunder F4320311600 @default.
• W2938369099 hasFunder F4320332193 @default.
• W2938369099 hasIssue "9" @default.
• W2938369099 hasLocation W29383690991 @default.
• W2938369099 hasLocation W29383690992 @default.
• W2938369099 hasOpenAccess W2938369099 @default.
• W2938369099 hasPrimaryLocation W29383690991 @default.
• W2938369099 hasRelatedWork W2551646801 @default.
• W2938369099 hasRelatedWork W2600874963 @default.
• W2938369099 hasRelatedWork W2766804807 @default.
• W2938369099 hasRelatedWork W2912147100 @default.
• W2938369099 hasRelatedWork W2913637396 @default.
• W2938369099 hasRelatedWork W2981977889 @default.
• W2938369099 hasRelatedWork W2982026403 @default.
• W2938369099 hasRelatedWork W3131125541 @default.
• W2938369099 hasRelatedWork W3188183888 @default.
• W2938369099 hasRelatedWork W4205243730 @default.

• next